Answers are grounded in this paper and cite their sources.
Retrospective analysis reveals HER2 expression's clinical relevance in metastatic prostate cancer, suggesting genomic implications.
252 Background: Evidence regarding the prevalence and clinical or biological relevance of Her2 expression in metastatic prostate cancer (mPC) remains limited. Methods: 52 patients (pts) with mPC (48 mCPHS, 4 mCRPC) were retrospectively analyzed. HER2 IHC was performed on FFPE primary and/or metastatic samples using the Dako HercepTest (Agilent platform), scored per gastric/solid-tumor criteria (0, 1+, 2+, 3+). Clinical and laboratory parameters were correlated with HER2 status (0 vs ≥1+). Genomic profiling included TP53, RB1, PTEN, and BRCA1/2. Progression-free survival (PFS) was defined from 1st-line therapy start to progression or death; overall survival (OS) from metastatic diagnosis. Survival was estimated by Kaplan–Meier and compared by log-rank test. Results: HER2 ≥1+ was observed in 59.6% of pts (IHC 1+ = 17%, 2+ = 21%, 3+ = 21%). Baseline characteristics are summarized in Table 1. HER2 0 tumors showed numerically higher rates of adverse clinical features, including ISUP 5 (50% vs 26%), ECOG ≥2 (21% vs 11%), visceral metastases (29% vs 16%), elevated LDH (43% vs 26%), and high-volume disease (57% vs 53%), none reached statistical significance (all p > 0.1). Molecularly, HER2 0 tumors were enriched for BRCA1/2 (24% vs 11%, p = 0.18), TP53 (58% vs 29%, p = 0.11), RB1 (42% vs 14%, p = 0.09), and PTEN (37% vs 7%, p = 0.04) alterations. The only TP53/RB1/PTEN triple-hit occurred in a HER2 0 tumor. No ERBB2 mutations were detected. Median PFS with 1st-line therapy in M1-HSPC pts was numerically shorter for HER2 0 versus HER2 ≥1+ (11.2 vs 16.8 months; HR 1.42, p = 0.18), with consistent trends across chemotherapy and non-chemotherapy regimens. OS was immature (median follow-up 17 months; 26% deaths). None of the pts received HER2-directed ADCs. At the time of submission, genomic results were available for 22 pts; sequencing of 20 additional cases is ongoing, while 10 were not evaluable due to tissue limitations. Conclusions: HER2 expression (IHC ≥1+) was present in approximately 60% of mPC cases. Although not statistically significant, HER2 0 tumors showed enrichment in TP53/RB1/PTEN/BRCA1/2 alterations and a trend toward shorter PFS, consistent across treatment subgroups. These findings suggest that loss of HER2 expression may define a genomically adverse subset of mPC that warrants further validation. Patient characteristics. Age, years – median (range) 69 (51–91) ECOG PS – n(%) 0 20 (38.5) ≥1 32 (61.5) HER2 expression (IHC) – n(%) 0 21 (40.4) 1+ 9 (17.3) 2+ 11 (21.2) 3+ 11 (21.2) HER2 tested Prostate Lymph node Extranodal metastasis Primary + metastatic site 46 (88.5%)1 (1.9%)2 (3.8%)3 (5.8%) Genomic alterations – n(%) BRCA2 4/22 (18%) BRCA1 1/22 (4.5%) Triple hit (PTEN+p53+RB1) 1/22 (4.5%) First metastatic presentation – n(%) mHSPC recurrent LV 5 (9.6) mHSPC de novo LV 13 (25.0) mHSPC recurrent HV 1 (1.9) mHSPC de novo HV 29 (55.8) mCRPC 4 (7.7) Sites of disease – n(%) Bone 41 (78.8) Lymph nodes 38 (73.1) Lung 10 (19.2)
No takes yet. Share an insight, caveat, or question.
Macias et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: